Finally, we compared C-13 with R406 (the active metabolite of Fostamatinib R788), a specific, ATP-competitive inhibitor of Syk (Syk IC50 = 41 nM) that has shown efficacy in the treatment of autoimmune diseases [34] and in preclinical leukaemia studies [35,36]. Here, SYK is linked to autoimmune disease.